July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Changes in Signs and Symptoms of Dry Eye Disease after using 0.1% or 0.05% Emulsions of Cyclosporine A Eye Drops
Author Affiliations & Notes
  • Jonatan Olafsson
    Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Øygunn Aass Utheim
    Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
    Department of Medical Biochemistry, Oslo University Hosptial, Oslo, Norway
  • Xiangjun Chen
    Faculty of Health Science, National Centre for Optics, Vision and Eye Care, University of Southeast Norway, Kongsberg, Norway
    Department of Ophthalmology, Drammen Hosptial, Drammen, Norway
  • Snorri Olafsson
    Telemark Hospital, Skien, Norway
    Loma Linda University Medical Center, Loma Linda, California, United States
  • Sten Raeder
    The Norwegian Dry Eye Clinic, Oslo, Norway
  • Darlene A Dartt
    Schepens Eye Reserach Institute/Massachussetts Eye and Ear/Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Behzod Tashbayev
    The Norwegian Dry Eye Clinic, Oslo, Norway
    Institute of Clinical Dentistry, Faculty of Dentistry, University of Oslo, Oslo, Norway
  • Tor Paaske Utheim
    Department of Ophthalmology, Oslo University Hospital, Oslo, Norway
    Department of Ophthalmology, Stavanger University Hospital, Stavanger, Norway
  • Footnotes
    Commercial Relationships   Jonatan Olafsson, None; Øygunn Utheim, None; Xiangjun Chen, None; Snorri Olafsson, None; Sten Raeder, None; Darlene Dartt, None; Behzod Tashbayev, None; Tor Utheim, None
  • Footnotes
    Support  Faculty of medicine, University of Oslo
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 912. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jonatan Olafsson, Øygunn Aass Utheim, Xiangjun Chen, Snorri Olafsson, Sten Raeder, Darlene A Dartt, Behzod Tashbayev, Tor Paaske Utheim; Changes in Signs and Symptoms of Dry Eye Disease after using 0.1% or 0.05% Emulsions of Cyclosporine A Eye Drops. Invest. Ophthalmol. Vis. Sci. 2018;59(9):912.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Dry eye disease (DED) is often accompanied by a T-cell mediated inflammatory response affecting the ocular surface and is in moderate and severe cases treated with cyclosporine A (CsA). Various formulations of topical CsA drops are used around the globe but evidence of a possible difference with regards to efficacy is lacking. This study compared post-treatment signs and symptoms in DED patients who used 0.1% CsA cationic emulsion (Ikervis, Santen) or 0.05% CsA emulsion of castor oil-in-water (Restasis, Allergan).

Methods : This retrospective study consecutively analyzed 200 patients with DED of different etiologies treated with Ikervis (n=100) or Restasis (n=100) over six months at the Norwegian Dry Eye Clinic from 2012-2017. Patients underwent a comprehensive work-up including ocular surface staining (OSS; Oxford grading scheme), fluorescein break-up time (FBUT), Ocular Surface Disease Index (OSDI) questionnaire, Schirmer’s test, and meibomian expressibility (ME) and quality (MQ). Increased ME and MQ may indicate meibomian gland dysfunction. All patients received preservative free tear substitutes in addition to CsA. Ocular surface staining, TFBUT, ME, and MQ-values were evaluated with Wilcoxon’s signed rank test (not normally distributed), OSDI-scores with a paired sample t-test and age with independent sample t-test (normally distributed), and gender with a chi-square test. Results are shown as means and standard deviations.

Results : Following six months of treatment with Ikervis or Restasis, both OSS and FBUT improved significantly, OSDI values improved only for Restasis, and MQ only for Ikervis. Schirmer’s test and ME did not improve in either group. See Table 1 for detailed results and Table 2 for patient demographics.

Conclusions : Ikervis did not demonstrate significant subjective improvement in contrast to Restasis. Only Ikervis showed an improvement in MQ score, suggesting a positive effect on the meibomian glands. This indicates a difference in efficacy between the drugs that should be further explored in a randomized controlled trial.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

 

Table 1 Results comparing Ikervis and Restasis over six months. *A decrease/†an increase is considered an improvement.

Table 1 Results comparing Ikervis and Restasis over six months. *A decrease/†an increase is considered an improvement.

 

Table 2 Patient demographics

Table 2 Patient demographics

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×